|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2009-2-23
|
|
pubmed:abstractText |
We studied dendritic, myeloid (mDCs) (BDCA1+/CD19-) and plasmacytoid cells (pDCs) (BDCA2+/CD123+) and B-cells (CD19+) at relapse, after short intravenous methyloprednisolone therapy and 30 days after treatment completion (remission period) and results were compared with a control group of healthy volunteers. We confirmed the decrease in BDCA2+/CD123+ after therapy (p=0.00006) and then an increase (p=0.0032) in comparison to the control group. The level of B CD19+ cells after GC therapy increased compared to the control group (p=0.00809) and had stabilised 30 days after therapy. The effect of methyloprednisolone on DC function and B-cell levels thus changes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD19,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Surface,
http://linkedlifedata.com/resource/pubmed/chemical/BDCA-1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CLEC4C protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Lectins, C-Type,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Methylprednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Immunologic
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0165-5728
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
207
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
107-10
|
|
pubmed:meshHeading |
pubmed-meshheading:19162336-Adrenal Cortex Hormones,
pubmed-meshheading:19162336-Adult,
pubmed-meshheading:19162336-Antigens, CD19,
pubmed-meshheading:19162336-Antigens, Surface,
pubmed-meshheading:19162336-B-Lymphocytes,
pubmed-meshheading:19162336-Dendritic Cells,
pubmed-meshheading:19162336-Female,
pubmed-meshheading:19162336-Flow Cytometry,
pubmed-meshheading:19162336-Humans,
pubmed-meshheading:19162336-Immunophenotyping,
pubmed-meshheading:19162336-Injections, Intravenous,
pubmed-meshheading:19162336-Lectins, C-Type,
pubmed-meshheading:19162336-Male,
pubmed-meshheading:19162336-Membrane Glycoproteins,
pubmed-meshheading:19162336-Methylprednisolone,
pubmed-meshheading:19162336-Middle Aged,
pubmed-meshheading:19162336-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:19162336-Receptors, Immunologic,
pubmed-meshheading:19162336-Statistics, Nonparametric,
pubmed-meshheading:19162336-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Changes in circulating dendritic cells and B-cells in patients with multiple sclerosis relapse during corticosteroid therapy.
|
|
pubmed:affiliation |
Department of Neurology, Medical University in Lublin, ul. Jaczewskiego 8, 20-090 Lublin, Poland. krystyna.mitosek@am.lublin.pl
|
|
pubmed:publicationType |
Journal Article
|
